NICE Rejects CAR-T Cancer Cell Therapy For Being Too Expensive.

August 29, 2018

Reuters (8/28, Hirschler) reports the UK’s National Institute for Health and Care Excellence rejected Gilead Sciences’ “cutting-edge CAR-T cell therapy for otherwise treatable forms of blood cancer” because its Yescarta (axicabtagene ciloleucel) product...